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The interleukin-10-deﬁcient (IL10−/−) mouse develops colon inﬂammation in response to normal intestinal microﬂora and has
beenusedasamodelofCrohn’sdisease.Short-ColumnLCMSmetaboliteproﬁlingofurinefromIL10−/− andwild-type (WT)mice
wasused, intwo independent experiments, to identify massspectral ionsdiﬀering in intensity between these two genotypes. Three
diﬀerential metabolites were identiﬁed as xanthurenic acid and as the glucuronides of xanthurenic acid and of α-CEHC (2,5,7,8-
tetramethyl-2-(2 -carboxyethyl)-6-hydroxychroman). The signiﬁcance of several diﬀerential metabolites as potential biomarkers
of colon inﬂammation was evaluated in an experiment which compared metabolite concentrations in IL10−/− and WT mice
housed, either under conventional conditions and dosed with intestinal microﬂora, or maintained under speciﬁc pathogen-free
(SPF) conditions. Concentrations of xanthurenic acid, α-CEHC glucuronide, and an unidentiﬁed metabolite m/z 495−/497+ were
associated with the degree of inﬂammationin IL10−/− mice and may prove useful as biomarkers of colon inﬂammation.
1.Introduction
Crohn’s disease is a chronic relapsing inﬂammatory disorder
of the bowel which is characterized by recurring episodes
of inﬂammation especially in the small and large intestine
accompanied by abdominal pain and persistent diarrhea [1].
Crohn’s disease has been attributed to a dysregulation of
the intestinal mucosal immune response towards normal
intestinal microﬂora and results from a complex interaction
of genetic [2, 3] and environmental factors [4]. The complex
aetiology and absence of a cure means that the management
of Crohn’s disease requires the continuing assessment of the
inﬂammation status of the patient so that the eﬃcacy of
treatments can be determined. Current methods of assessing
bowel inﬂammation require the sampling of intestinal tissue
for histological evaluation or blood for measuring plasma
biomarkers of inﬂammation. Metabolomic characterization,
largelybyNMR,ofurine[5],faeces[6–8],andcolonmucosal
tissues [9] from Crohn’s disease patients has revealed a range
of metabolites whose concentrations are perturbed in asso-
ciation with established inﬂammation. Urinary biomarkers
predictive of inﬂammation status would be preferable to
sampling of intestinal tissue or blood as the collection of
urine samples is relatively noninvasive and multiple samples
can more readily be obtained.
A number of metabolomic studies of mouse models
of Crohn’s disease have been used to study the biochem-
ical changes associated with inﬂammation and to identify
possible biomarkers. LCMS metabolite proﬁling of serum
from mice treated with dextran sulphate sodium (DSS)
to induce colitis showed that colon inﬂammation was
increased by DSS-inhibition of stearoyl-CoA desaturase 1
(SCD1)-mediated oleic acid biogenesis [10]. Examination
by NMR of colonic mucosal samples from Sprague Dawley
rats treated with 2% carrageenan for 1 or 2 weeks to
induce inﬂammation showed increases in concentrations
of creatinine, phosphatidylcholine and unsaturated lipids
[11]. The interleukin-10-deﬁcient (IL10−/−) mouse shows2 Journal of Biomedicine and Biotechnology
physiological,and biochemicalsimilarities toCrohn’s disease
[3] including the development of intestinal inﬂammation
in response to the presence of intestinal microﬂora and
has been widely used as a model of Crohn’s disease [12].
Interleukin-10(IL10)isanimmunosuppressivecytokinethat
down-regulates cell-mediated immune responses and has an
important role in maintaining intestinal mucosal immunity
[13]. Metabolic proﬁling of plasma of IL10−/− mice by NMR
indicated the inﬂamed state was characterised by impaired
metabolism of glyco- and lipoproteins and loss of energy
homeostasis with higher levels of fatty acid oxidation and
glycolysis and interconversion of amino acids to produce
energy [14]. NMR metabolite proﬁling of 24-hour pooled
urine [15] and GCMS analysis of spot urine samples [16]
from IL10−/− mice identiﬁed changes in urinary metabolites
associated with colon inﬂammation providing insights into
biochemical changes associated with disease progression. In
particular, fucose and xanthurenic acid were identiﬁed as
early biomarkers of inﬂammation in the urine of IL10−/−
mice [17].
The use of multiple metabolomic platforms extends the
range of metabolites and hence the possible perturbations
in biochemical pathways that may be observed. Recently,
in a cross-platform comparison of metabolomics methods,
LCMS was recommended as providing the best combination
of versatility and robustness on a single platform [18].
Direct infusion (DI) MS/MS [19, 20] is a recently developed
metabolomic analysis tool developed for the rapid screening
of complex biological samples. DI-MS/MS combines the
analytical power of MS/MS for metabolite characterisation
with the advantages of minimal sample handling and high
sample throughput.
For nontargeted urinary metabolite proﬁling, we have
modiﬁed the DI-MS/MS procedure using a short 20-mm
reversed-phase column (Short-Column LCMS) to separate
and discard to waste highly ionic material and urea which
would otherwise dominate the MS data [21]. In this study,
wedemonstratetheuseofthismethodologytorapidlyscreen
sample sets and to identify metabolite diﬀerences between
the urine from IL10−/− and wild-type mice that were not
detected with other techniques. Structural identiﬁcation of
three of these diﬀerential metabolites using MS/MS, high
resolution MS, and chemical synthesis has provided further
insight into the metabolic changes associated with the
IL10−/− deﬁciency.Finallytheusefulnessofthesemetabolites
as biomarkers of colon inﬂammation was tested in an
experiment where IL10−/− mice were either dosed with
intestinal microﬂora to initiate inﬂammation or maintained
under speciﬁc pathogen-free (SPF) conditions to limit the
development of inﬂammation.
2.Materialsand Methods
2.1. Animal Experiments. All animal studies were reviewed
and approvedby theCrown Research InstituteAnimal Ethics
Committeein Hamilton,NewZealand,accordingtotheNew
Zealand Animal Welfare Act (1999). Male IL10−/− mice of
C57BL/6 background strain (B6.129P2-Il10tm1Cgn)a n dw i l d -
type C57BL/6 mice (The Jackson Laboratory, Bar Harbor,
Maine, USA) of average age upon arrival of 4, 5.3, and
4.4 weeks old were used for experiments 1, 2 [16], and
3[ 17], respectively. For experiments 1 and 2 (Figure 1),
each mouse was housed individually in a shoebox-style cage
under conventional conditions and fed powdered AIN76A
diet with food intake adjusted to equal the mean amount
of food consumed by IL10−/− mice the previous week.
Four days after arrival, mice were orally dosed with a
mixture of Enterococcus faecalis, E. Faecium,a n dc o m p l e x
intestinal ﬂora to ensure the same initial microbial exposure
and the development of consistent intestinal inﬂammation
[22]. In experiment 1, yellow-ﬂeshed kiwifruit (Actinidia
chinensis) and in experiment 2, green-ﬂeshed kiwifruit
(A. delicoisa “Hayward”), fruit extracts were added to
the diets of some mice [16] to test their possible anti-
inﬂammatory eﬀects [23]. Transcriptomic and proteomic
results of diet treatments will be reported elsewhere. In
experiment 3, all mice were fed powdered AIN76A diet
only. Approximately half the IL10−/− and wild-type mice
weremaintainedunderconventionalconditionsasaboveand
the other half were maintained under SPF conditions and
not dosed with intestinal microﬂora to maintain a lower
level of colon inﬂammation in the IL10−/− mice throughout
the experiment [17]. Spot urine samples were collected
from each experiment on four collection days when the
average age of mice was 5.5, 7, 8.5, and 10.5 weeks old
(experiment 1), 7, 9, 11.5 and 12 weeks old (experiment 2)
[16],and6.3,8.0,9.4and10.4weeksold(experiment3)[17].
Final urine samples for experiments 1 and 2 were collected
immediately before mice were euthanized and after a cycle
of feeding, fasting, and feeding designed to standardize the
timing of the ﬁnal food intake. Mice from each treatment
of experiment 3 were euthanized after three and six weeks
for histology and measurement of serum amyloid-A (SAA)
protein concentrations [17].
2.2. Sample Preparation of Urine for LCMS. Urine (4μL) was
diluted with 0.1% formic acid (200μL) in an Eppendorf
tube, centrifuged at 12100 g for 2 minutes to precipitate
particulates and an aliquot transferred to a vial before
injection into the LCMS. Randomised batches of samples for
each time point were analyzed sequentially.
2.3. Short-Column LCMS for Biomarker Identiﬁcation. Sam-
ples were analyzed by a rapid LC-MS procedure [21]u s i n g
a Thermo Surveyor pump and auto-sampler connected to
a Thermo LTQ linear ion-trap mass spectrometer (Thermo
Electron Corporation, San Jose, CA) using negative electro-
spray ionization. The capillary temperature was 275◦Ca n d
source ionization voltage was −4000V. A 20μL aliquot of
diluted urine was loaded onto a Strata-X on-line extraction
cartridge (20 × 2.0mm, Phenomenex, Torrence, CA) with
water (300μLmin −1). For the ﬁrst 0.5min. the ﬂow from the
cartridge was diverted away from the mass spectrometer to
waste, after which all ﬂow entered the electrospray source.
Samples were eluted with a gradient comprising water
containing 0.1% formic acid (A) and acetonitrile containing
0.1%formicacid(B).ThecartridgewaselutedwithsolventAJournal of Biomedicine and Biotechnology 3
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Figure 1: Overall design of mouse experiments 1, 2, and 3 and process used to identify and validate urinary biomarkers of colonic
inﬂammationin the IL10−/− mouse model of Crohn’s disease.
for1.5 min, thenwith a linear gradient to 100% B over3min
and held at 100% B for 3min. The initial solvent (100% A)
was restored over a 0.5-minute linear gradient and eluted
for 1.5min at 600μLmin −1 and for 0.5min at 300μLmin −1.
The ion trap was programmed to collect an MS1 spectrum
from100 to1000m/z followed by MS2 and MS3 spectra from
collision-induced dissociation of the most intense ions in
the MS1 spectrum, using a 12-second exclusion list to cycle
through coeluting ions.
2.4. LCMS/MS for Metabolite Characterization. Samples
selected for further metabolite characterisation were ana-
lyzed by LCMS/MS in negative and positive electrospray
ionization mode using a Thermo LTQ ion-trap mass spec-
trometerwith temperatureand voltagesettingsas above.The
HPLC system consisted of two binary Jasco X-LC 3185PU
pumps (Jasco Corporation, Tokyo, Japan) connected to a
HTS-PAL auto-sampler (CTC Analytics, Zwingen, Switzer-
land). A 15μL aliquot of diluted urine was loaded onto
a Luna C18 column (150 × 2.0mm, 5μmp a r t i c l es i z e ,
Phenomenex, Torrence, CA)with a mobile phase ﬂow rate of
200μLmin −1. For the ﬁrst 3min, the ﬂow from the column
was diverted away from the mass spectrometer to waste, after
which all ﬂow entered the electrospray source. Samples were
eluted with a gradient comprising water containing 0.1%
formic acid (A)and acetonitrile containing 0.1% formic acid
(B). The gradient was 95% solvent A for the ﬁrst 3min,
then a linear gradient to 98% B over 27min. This was held
at 98% B for 3min and then the initial solvent (95% A)
was restored over a 1min linear gradient and re-equilibrated
for 6min. The ion trap was programmed to collect a MS1
spectrum from 150 to 850m/z followed by MS2,M S 3,a n d
MS4 spectra from collision- induced dissociation of the most
intense targetionfromaparentionlistcomprisingcandidate
negative ions as in Table 1 or the appropriate product ion
spectrum. MS data was analysed with XCalibur software
(ThermoElectronCorporation,SanJose,CA).Iontreeswere
compiled from extracted product ion spectra.
2.5. UHPLC-MS. Samples were analyzed using a Jasco X-
LC UHPLC and HTS-PAL autosampler connected to the
LTQ with instrument settings as described above. A 20μL
aliquot of diluted urine was loaded onto a Zorbax SB-C18
UPHLC column (50 × 3.0mm, 1.8μm particle size, Agilent
Technologies, Santa Clara, CA, USA) with a mobile phase
ﬂow rate of900μLmin −1.Fortheﬁrst 0.7min, the ﬂow from
the column was diverted away from the mass spectrometer
to waste, after which all ﬂow entered the electrospray source.
Samples were eluted with a gradient comprising water
containing 0.1% formic acid (A) and acetonitrile containing
0.1% formic acid (B). The gradient was 95% solvent A for
the ﬁrst 0.5min, then with a linear gradient to 100% B over
4.5minandthenrestoredtotheinitialsolvent(95%A)overa
0.5minlineargradientandre-equilibratedfor2min.Theion
trap was programmed to collect an MS1 spectrum from 100–
1000m/z followed by MS2 and MS3 spectra from collision-
induced dissociation of the most intense ions in the MS1
spectrum, using a 4-second exclusion list to cycle through
coeluting ions.4 Journal of Biomedicine and Biotechnology
Table 1: Biomarker Candidate ions (m/z) selected from Short-Column LCMS and LC-MS/MS analysis of urine samples from IL10−/− and
wild-type (WT) mice.
Short-Column LCMS
Biomarker ion (m/z)
Average fold change
Log2(IL10−/−/WT)
P value Early diﬀerence
observed Identiﬁcation,
Negative ions
204 1.8 (expt. 1) <.01 (FDR <0.05) Y xanthurenic acid
2.5 (expt. 2) <.01 (FDR <0.05)
308 −1.5 (expt. 1) <.01 (FDR >0.05)) ? (expt. 1) unknown
−1.8 (expt. 2) <.01 (FDR <0.05) Y( e x p t .2 )
380 −1.1 (expt. 1) >.01 N( e x p t .1 ) xanthurenic acid
glucuronide
−1.6 (expt. 2) >.01 Y( e x p t .2 )
453 −1.5 (expt. 1) <.01 (FDR >0.05) N( e x p t .1 ) α-CEHC glucuronide
−2.0 (expt. 2) <.01 (FDR <0.05) Y( e x p t .2 )
495 −1.5 (expt. 1) <.01 (FDR >0.05) Y (expt. 1) unknown
−2.2 (expt. 2) <.01 (FDR <0.05) Y( e x p t .2 )
Positive ions
206 1.7 (expt. 1) <.01 (FDR <0.05) Y (expt. 1) xanthurenic acid
1.2 (expt. 2) >.01 N( e x p t .2 )
382 −1.2 (expt. 1) >.01 N( e x p t .1 ) xanthurenic acid
glucuronide
−1.5 (expt. 2) <.01 (FDR <0.05) Y( e x p t .2 )
497 −1.2 (expt. 1) >.01 Y (expt. 1) unknown
−1.4 (expt. 2) <.01 (FDR <0.05) Y( e x p t .2 )
2.6. High Resolution (HR) Mass Spectrometry. Salts and
urea were removed from a pooled IL10−/− urine sample
by elution of the sample and an aqueous wash through
a C-18 SPE cartridge, and the 80% methanol eluate was
collected for MS analysis. The eluate was infused into an
LTQ-FTMS (Thermo Electron Corporation, San Jose, CA,
USA) for MS/MS and high resolution MS analysis under
both positive and negative electrospray ionisation condi-
tions. HR ions observed for xanthurenic acid were negative
ions, MS2 product ion (m/z 204 → 160) m/z 160.0405
([M–H–CO2]−,C 9H5O2N− requires 160.0398) and posi-
tive ions MS1m/z 206.0450 ([M+H]+,C 10H7O4N+ requires
206.0448), and MS2 product ion (m/z 206 → 188) m/z
188.0344(C10H5O3N+ requires188.0347).HRionsobserved
for α-CEHC glucuronide were MS1m/z 453.1773 ([M–H]−,
C22H29O10
− requires 453.1761) and m/z 435.1664 ([M–H–
H2O]−,s o u r c ef r a g m e n t ) ,C 22H27O9
− requires 435.1655).
HR LCMS ions observed for xanthurenic acid glucuronide
were MS1m/z 382.0762 ([M+H+], C16H16NO16 requires
382.0774) and MS2 product ion m/z 206.0450 (C10H8NO4
requires 206.0453).
2.7. Bioinformatic Analysis of Short-Column LCMS/MS Data.
Raw data (positive and negative ionization) were converted
to mzXML format. Nominal mass binning (integer m/z ±
0.5) was carried out for the full m/z range of 100 to 1000
resulting in 901 nominal bins for each individual sample.
Signal intensity at nominal mass resolution was retrieved
using continuous wavelet transform (CWT) algorithms [24]
for peaks within each bin with S/N > 3 (noise deﬁned as
95% quantile ofabsolute CWT coeﬃcientsofscale one). The
median peak intensity of the identiﬁed peaks in each bin was
used to represent the intensity of that bin. Peak intensity was
then normalised by a linear regression of log ion intensity
against run sequence. Empirical Bayes moderated t statistics
[25] (R Limma package) were applied to identify MS1 ions
that were signiﬁcantly diﬀerent (FDR adjusted P<. 05)
between samples from IL10−/− and wild-type mice in each
experiment. Linearmodelling ofthefull factorial designwith
three factors (genotype, diet (experiments 1 and 2), and day
of collection of urine samples) was also carried out for each
experiment. No signiﬁcant diet eﬀects were found for the
metabolites discussed below.
2.8. Metabolite Identiﬁcation. Possible metabolite structures
were inferred from MS/MS ion trees and high resolution
FTMS data using web-based metabolite databases [26]a n d
by comparison with authentic compounds and published
mass spectral fragmentation pathways where available. Xan-
thurenic acid was obtained from Aldrich Chemical Co.
Xanthurenic acid sulphate dipotassium salt was prepared by
chemical synthesis [27]. α-CEHC glucuronide was synthe-
sised following the method of Pope et al. [28].
3.Results
3.1. Short-Column LCMS Data Analysis. To identify
metabolic diﬀerences between IL10−/− and wild-type mice,Journal of Biomedicine and Biotechnology 5
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Figure 2: Short-Column LCMS ion chromatogram for m/z 231 showing broad partially resolved peaks typically obtained on desorption
of analytes from the 20mm Strata-X on-line extraction cartridge. Wavelet algorithms were used to identify local peaks, and the median
intensity of these peaks was taken to represent the intensity of m/z 231.
urine samples were collected at four time points from
each of two independent experiments (experiments 1 and
2) [16]( Figure 1). Short-Column LCMS using a short
(20mm) solid phase extraction column enabled extremely
rapid sample analysis (8 minutes per sample) and avoided
blocking the source with salt build-up but provided only
minimal chromatographic separation of analytes. The LCMS
data for each sample consisted of broad peaks of varying
signal intensity oneach of theunit mass channels of the mass
spectrometer (Figure 2). LCMS data ﬁles were processed
based on methods developed for the direct-infusion LCMS
data analysis [29] but with notable modiﬁcations. With
the short solid phase extraction column used in these
experiments, the signal distributions within mass bins varied
with time with variable and non-Gaussian chromatographic
peaks. Robust statistics were needed to summarise the
signal intensities within each mass bin. Wavelet-based signal
identiﬁcation was used to identify any m/z peaks within
each bin with S/N > 3[ 24] with the median average of the
identiﬁed peaks in each bin being used to represent the
intensity of that bin.
A progressive decline in ion intensity, as observed by
Koulman et al. [20], was observed during the infusion of
the large number of urine samples. Several normalization
approaches [30] including linear regression, local regression
loess and quantile were tested to correct for this decline.
The loss of ion intensity was best explained by a linear
relationship betweenthe log ofion intensity and the position
of samples in the run sequence. Normalization based on this
model was carried out for all MS ions and the normalized
data were subjected to statistical analysis.
3.2.Selection ofBiomarker Candidate Ions from Short-Column
LCMS Data. MS1 ions that were signiﬁcantly diﬀerent (FDR
adjusted P-value P<. 05) between samples from IL10−/−
and wild-type mice in each experiment were identiﬁed
using empirical Bayes moderated t-statistics [25] (R Limma
package) (Supplementary Materials available online at doi:
10.1155/2011/974701, Table S1). More diﬀerential metabo-
lites were found by negative mode Short-Column LCMS,
however, there was also a pleasing correspondence between
the top candidate ions identiﬁed in both experiments (1 and
2) and to a lesser extent between candidate ions identiﬁed in
bothpositiveandnegativeionisationmodes.Fromthisinitial
list, biomarker candidates were selected for further investi-
gation based on additional criteria: the detection and level
of signiﬁcant of ions in both experiments, detection early in
the experiment, detection as both positive and negative ions,
and the presence of suﬃcient peak intensity to allow detailed
MS/MSanalysis. A morecomplex analysis using linear mixed
modelling to incorporate eﬀects of diet and the metabolic
variation of individual mice was used to evaluate changes6 Journal of Biomedicine and Biotechnology
in the metabolic responses over time but did not produce
additional candidate ions discriminating the IL10−/− mice.
LC-MS/MS analysis of selected samples was then carried out
to identify which candidate ions (and ion trees) identiﬁed
from Short-Column LCMS analysis corresponded to single
orto multiple metabolites, to eliminate source fragment ions
and adducts, and to obtain expanded MS/MS ion trees of
chromatographically resolved metabolites of interest. The
mass spectral ions selected by these criteria are listed in
Table 1.
3.3. Structural Characterization of Biomarker Candidates
3.3.1. Xanthurenic Acid (m/z 160, 204 [M–H]− and m/z 206
[M+H]+). Three major metabolites with m/z 204− were
detected in mouse urine by LCMS of which only the major,
and earliest eluting metabolite, was elevated in the urine
from IL10−/− mice. This metabolite co-eluted with the only
signiﬁcant m/z 160− i o ni nt h es a m p l e s( a l s oe l e v a t e di n
IL10−/− mice), a likely source fragment which was shown
to arise from the m/z 204− ion, (loss of 44 amu) by
MS/MS. High resolution FTMS and LCMS comparison with
authentic material identiﬁed this metabolite as xanthurenic
acid.
3.3.2. Xanthurenic Acid Glucuronide (m/z 380 [M–H]− and
m/z 382 [M+H]+). LCMS identiﬁed the negative ions at m/z
380 and the positive ion at m/z 382 as resulting from the
same metabolite that occurred at lower concentrations in
the urine from IL10−/− mice (Table 1). LC-MS/MS showed
loss of a glucuronide-derived fragment (176 amu) in both
negative and positive ionization modes to form a product
ion (m/z 204 or 206 resp.) which underwent further frag-
mentations as observed for the corresponding xanthurenic
acid ions (Figure 3). High resolution MS data is consistent
with xanthurenic acid glucuronide, although this remains
to be conﬁrmed by chemical synthesis. Xanthurenic acid
glucuronide was identiﬁed as a diﬀerentiating metabolite
(FDR adjusted P<. 05) in both positive and negative
ion LCMS and in both experiments 1 and 2, but with
concentrations changing in the opposite direction to that of
its aglycone (Table 1).
3.3.3. α-CEHC Glucuronide (2,5,7,8-Tetramethyl-2-(2 -
Carboxyethyl)-6-Hydroxychroman Glucuronide, m/z 453 [M–
H]−). The ion (m/z 453−) occurred at lower concentrations
in urine from IL10−/− mice. A metabolite (M+ 454) not
containing nitrogen was assumed. LC-MS/MS analysis
identiﬁed this metabolite as a second glucuronide (MS2
loss of 176 amu to m/z 277) with a subsequent loss of 44
amu, implying a glucuronide acid conjugate. The molecular
formulatherefore requiresa minimum ofnine oxygenatoms.
FTMS analysis indicated that the major m/z 453− ion in the
sample showed the required ion tree and had an accurate
mass of 453.1773. Constraining any molecular formula to
a minimum of 9 oxygen atoms gave C22H29O10
− as the
most likely formula for this ion (theoretical value 453.1761).
Similarly, the major fragment ion at m/z 435.1664 (loss of
18 amu) is assigned a formula of C22H27O9 (theoretical
value 435.1655). The molecular formula is then C22H30O10
with C16H22O4 being the formula of the aglycone (a
carboxylic acid). A search for such aglycones in the Human
Metabolome Database [31] suggested that this metabolite
was the glucuronide of α-CEHC. The MS/MS fragmentation
appeared consistent with this structure (Figure 4). α-CEHC
glucuronide was prepared by synthesis [28]a n dt h eM S / M S
and LCMS matched that of the urine metabolite. α-CEHC
is a major water-soluble metabolite of vitamin E, which
circulates in the blood and is excreted in the urine [28].
3.3.4. Unidentiﬁed Metabolites. The m/z 284− ion was
detected amongst the most signiﬁcant diﬀerentiating species
between IL10−/− and wild-type mice (Table S1), and xan-
thurenic acid sulphate, a known urinary metabolite of
xanthurenic acid [27], seemed a likely candidate. UHPLC-
MS analysis, however, showed that this ion was an isotopo-
logue of m/z 283−, also a highly signiﬁcant diﬀerentiating
species (Table S1), and eluted at a later retention time than
authentic xanthurenic acid sulphate [27]. Xanthurenic acid
sulphate(m/z284[M–H]−)wasnotdetectedbyUHPLC-MS
(Experiment 3) using an authentic standard.
Two additional ions (m/z 308− and m/z 497+/495−)w e r e
signiﬁcantly reduced in urine from IL10−/− mice (Table 1).
The ﬁrst metabolite (m/z 308) was found only as a negative
ion, and LC-MS/MS analysis (MS2 m/z 124, MS3 m/z 107,
80) suggested a taurine conjugate. The second pair of ions
(m/z 497+/495−) would seem to be derived from the same
metabolite as they appear at the same retention time on
LCMS/MS with the same losses of 147 and 75 (glycine)
amu from the corresponding pseudomolecular ions. The
structures of these metabolites remain unknown.
3.4. Evaluation of Candidates as Biomarkers of Colon Inﬂam-
mation. The biological signiﬁcance of these metabolic dif-
ferences as biomarkers of colon inﬂammation was evaluated
in experiment 3 that compared IL10−/− and wild-type
mice housed either under conventional conditions and
dosed with intestinal microﬂora or maintained under SPF
conditions without dosing with intestinal microﬂora [17].
The rationale for this experiment was that biochemical
diﬀerences arising from colon inﬂammation in IL10−/−
mice should be reduced when these mice were maintained
under SPF conditions [3]. Biochemical diﬀerences arising
from other genetic diﬀerences between the mouse strains
[32] or as a consequence of microbial dosing should not
be similarly aﬀected. IL10−/− mice housed under these
SPF conditions showed decreased colon inﬂammation as
measured by histology scores and SAA levels in serum [17].
Urine samples were analyzed using UHPLC-MS in both
positive and negative ionisation modes with both targeted
analysis of biomarker candidates and untargeted metabolic
proﬁling of all metabolites. The top scoring metabolites
identiﬁedasdiﬀeringbetweenIL10−/− andwild-typemiceby
untargeted analysis included xanthurenic acid, xanthurenic
acid glucuronide, and α-CEHC glucuronide among the top
20 candidates (Supplementary Table S2: ion labels belowJournal of Biomedicine and Biotechnology 7
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Figure 3: LC-MS/MS ion trees (positive ions) for A, xanthurenic acid (m/z 206 [M–H]−) and B, xanthurenic acid glucuronide (m/z 382
[M–H]−)s h o w i n gm a j o r( >80% relative intensity), intermediate (≥30 ≤80%), and minor (>1 <30%) MS/MS fragmentations using bold,
normaland dotted arrows, respectively.
refer to this table). Amongst the positive ions m/z 206
(M206T94), with isotopologues m/z 207 and 208, was the
top ranking candidate showing an average 2.4-fold increase
(P<. 0001) in urine from IL IL10−/− mice. However, the
corresponding negative ion (M204T91) was only the 21st
ranking candidate despite the high ranking for this ion in
previous experiments. Targeted analysis of xanthurenic acid
monitoring the m/z 204− MS1 i o ni nn e g a t i v em o d es h o w e d
interference from a closely eluting metabolite.
Xanthurenic acid concentrations were signiﬁcantly
higher in dosed mice (P = .002) with this increase
being more apparent between the dosed and SPF IL10−/−
animals (P<. 001). In addition, SPF IL10−/− mice showed
an increase in xanthurenic acid concentrations from the
earliest timepoint (P<. 001) supporting the hypothesis
that xanthurenic acid is an early biomarker of inﬂammation
and consistent with the increasing histology scores and SAA
concentrations measured for these mice [17].
UHPLC-MS analysis conﬁrmed that xanthurenic acid
glucuronide (M382T85 and M380T82) occurred at signiﬁ-
cantly higher concentrations in urine from WT mice (P<
.0001) (Figure 5) and showed that, while concentrations
of this metabolite increased throughout the experiment
in both types of mice (P<. 001), concentrations in
IL10−/− mice were not aﬀected by housing conditions (SPF
or conventional) (P = .5) . We therefore conclude that
the diﬀerence in concentrations of this metabolite between
IL10−/− and WT mice represents a metabolic diﬀerence
between the two mouse strains unrelated to the state of
inﬂammation [17, 32]. Concentrations of this metabolite
increased with time in IL10−/− mice under SPF conditions.
However, similar increases also occurred in WT mice and
would seem to be related to the age of the mice rather than
to inﬂammation.
UHPLC-MS analysis showed that α-CEHC glucuronide
(M453T145) occurred at signiﬁcantly higher concentrations
in urine from WT mice (Figure 6) and at higher concen-
trations when either IL10−/− or WT mice were housed
under SPF conditions (P<. 0001). The concentration
of this metabolite in urine from WT mice was unaltered
o v e rt h ec o u r s eo ft h ee x p e r i m e n t( P = .5) but decreased
(P = .02) in the IL10−/− mice under both SPF and
conventional conditions. Overall these results suggest that
reduced concentrations of α-CEHC glucuronide may serve
as a marker of inﬂammation status in the IL10−/− mice
The metabolite with ions M495T117/M497T116
appeared as the 29th and 41st ranking ions that were
signiﬁcantly diﬀerent between IL10−/− and wild-type8 Journal of Biomedicine and Biotechnology
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Figure 5: Relative concentrations of xanthurenic acid (M206T94) and xanthurenic acid glucuronide (M380T82, m/z 380 ([M–H]−),
identiﬁed by LCMS/MS) measured by UHPLC-MS in urine samples from IL10−/− and wild-type (WT) mice housed either under
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Figure 6: Relative concentrations of α-CEHC glucuronide mea-
sured by UHPLC-MS in urine samples from IL10−/− and wild-
type (WT) mice housed either under conventional conditions
and dosed with intestinal microﬂora or maintained under speciﬁc
pathogen free (SPF) throughout the experiments. Urines samples
were collected 7, 19, 29, and 36 days after dosing [17].
samples. Both ions occurred at signiﬁcantly lower
concentrations (P<. 001) in urine from IL10−/− mice
(Figure 7) conﬁrming results obtained by Short-Column
LCMS; however, this suppression was partially removed
by SPF treatment (Treatment eﬀect P<. 001 for m/z 495
and P = .03 for the less intense m/z 497 ion). Metabolite
concentrations in urine from IL10−/− mice were signiﬁcantly
reduced as a result of microbial dosing (P<. 0001).
Concentrations of the more intense m/z 495− ion were also
signiﬁcantly reduced with time (P = .014 overall; P<. 001
for IL10−/− mice). These results suggest that reduced
concentrations of this metabolite were related to the extent
of colon inﬂammation in the IL10−/− mouse.
UHPLC-MS analysis conﬁrmed that the metabolite with
m/z 308 (M308T85) occurred at slightly higher concentra-
tions in urine from IL10−/− mice (P<. 0001) and showed
thatconcentrationswere reducedinurinefrom IL10−/− mice
under SPF conditions (P = .003) (Figure 8). However, the
downward trend inurinary concentrationsofthismetabolite
with time for all treatments (P<. 0001) suggested that its
elevated concentrations in IL10−/− mice was not associated
with colon inﬂammation.
4.Discussion
Xanthurenic acid was previously identiﬁed by GCMS as an
early biomarker of inﬂammation in urine from IL10−/− mice
[16, 17] and is a product of tryptophan catabolism through
the kynurenine pathway. This pathway is activated by proin-
ﬂammatory stimuli such as bacterial lipopolysaccharides
and interferon-γ cytokine [33]; however, metabolites of this
pathway are also associated with the induction of immune
tolerance [33–35]. Thus the elevated levels of xanthurenic
2
4 M495T117
Wild-type IL10−/−
Day
1234 1234 1234 1234
Dosed SPF Dosed SPF
R
e
l
a
t
i
v
e
a
m
o
u
n
t
Figure 7: Relative concentrations of biomarker M495T117 (m/z
495−) measured by UHPLC-MS in urine samples from IL10−/− and
wild-type (WT) mice housed either under conventional conditions
and dosed with intestinal microﬂora or maintained under speciﬁc
pathogen free (SPF) throughout the experiments. Urines samples
were collected 7, 19, 29, and 36 days after dosing [17].
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Figure 8: Relative concentrations of biomarker M308T85 (m/z
308−) measured by UHPLC-MS in urine samples from IL10−/− and
wild-type (WT) mice housed either under conventional conditions
and dosed with intestinal microﬂora or maintained under speciﬁc
pathogen free (SPF) throughout the experiments. Urines samples
were collected 7, 19, 29, and 36 days after dosing [17].
acid in urine from IL10−/− mice may result from the absence
of negative feedback control by IL10 on the production of
kynurenine metabolites.
Xanthurenic acid glucuronide, identiﬁed on the basis of
its high resolution LC-MS/MS fragmentation pattern, was
also a diﬀerential metabolite. Concentrations of the glu-
curonide were lower in urine from IL10−/− mice suggesting
a shift to higher free xanthurenic concentrations associated10 Journal of Biomedicine and Biotechnology
with colon inﬂammation. However, the low urinary con-
centration of the glucuronide in IL10−/− mice kept under
SPF conditions suggested its concentration was not related
toinﬂammation status.Similarobservations havebeenmade
for short chain dicarboxylic acids that occurred at reduced
concentrations in the urine of IL10−/− mice regardless of
inﬂammation status [17]. The origin of such metabolic
diﬀerences was attributed to residual 129P2 embryonic stem
cell-derived genetic material ﬂanking the IL10 gene in the
IL10−/− C57BL/6 mouse [17, 32]. The UDP glucuronosyl-
transferase (UGT1) gene family (http://www.ensembl.org/)
also lies within this region of embryonic stem cell-derived
genetic material and may contribute to this metabolic
diﬀerence between mouse strains. Xanthurenic acid 8-O-
sulphate and 8-O-glucoside have also been identiﬁed in
human urine as natriuretic hormones that regulate sodium
excretion by the kidney [27]. Xanthurenic acid sulphate was
not detected in the present study while xanthurenic acid
glucoside(m/z 366 [M-H]−) was only tentatively detected by
UHPLC as the diﬀerential metabolite (M366T84) (Table S2);
higher in the urine from IL10−/− mice.
α-CEHC is a degradation product of vitamin E normally
present inurine [28] where its concentrationmay reﬂect that
of α-tocopherol and of α-CEHC in the liver [36]. Vitamin E
is reduced in serum from Crohn’s disease patients possibly
as a result of reduced concentrations of serum lipids and of
reduced absorption of lipids from the diet [37]. The reduced
concentrations of α-CEHC glucuronide observed in urine
of IL10−/− mice, and their recovery under SPF conditions,
is consistent with reduced availability, degradation, and
excretion of vitamin E in mice with impaired intestinal
function. Reduced concentrations of α-CEHC glucuronide,
and of the related metabolite γ-CEHC β-D-glucoside, have
also been identiﬁed in urine of mice treated with a pregnane
X receptor (PXR) activator [38]. It was suggested that these
conjugates in urine may be useful urinary biomarkers of
PXR activation. PXR is highly expressed in the intestines
where it functions as a xenosensor to regulate the expression
of metabolic enzymes and the excretion of xenobiotics
as well as of toxic endogenous metabolites such as bile
acids [39]. PXR activation was shown to be protective
in the DSS-induced colitis mouse model of inﬂammatory
bowel disease [40]. In IL10−/− mice, increased intestinal
permeability may likewise result in an increased ingress of
xenobiotics and toxic endogenous metabolites such as bile
acids resulting in activation of PXR and reduced urinary
vitamin E metabolites. Urinary α-CEHC glucuronide may
thus serve as a good biomarker of intestinal inﬂammation.
The discovery of α-CEHC glucuronide and other
unknown metabolites as potential inﬂammatory biomarkers
illustrates both the power and the limitations of cur-
rent analytical techniques in metabolomic analysis. Short-
Column LCMS analysis enables extremely rapid metabolic
proﬁling of multiple samples with simultaneous collection
of characterising MS/MS data. However, the limited sepa-
ration of individual metabolites hinders the structural and
biochemical characterisation of candidate ions and their
biological validation. UHPLC-MS allows rapid measure-
ment of chromatographically individual metabolites but
with reduced mass spectral data, so that additional MS
experimentation is required to characterise metabolites of
interest. The challenge of metabolite identiﬁcation remains
a major constraint butis essential for biological validation of
biomarker candidates. Comparison of our results with those
obtained from other metabolomics studies of urine from
Crohn’s disease patients or from animal models indicates
how the diﬀerent analytical tools each brings their own
selectivity [18] so that the application of new analytical
technology, as here, will reveal new metabolic biomarkers.
NMR proﬁling of urine from Crohn’s and ulcerative colitis
patients has identiﬁed a number of metabolites aﬀected
by gut microbes, such as formate, hippurate, and p-cresol
sulphate, which were able to discriminate between the
patientcohorts[5].Methylhistidine, glycine,guanidoacetate,
and citrate were further metabolites important in distin-
guishing between cohorts. Methylhistamine has previously
been reported as a urinary marker of disease activity in
Inﬂammatory Bowel Disease [41]. However, hippurate, p-
cresol sulphate, methylhistidine, and methylhistamine were
not detected as diﬀerentiating metabolites in the present
study. More recently, Lin et al. using GCMS [16, 17]h a v e
proposedxanthurenicacidandfucoseasearlydiscriminating
metabolites of colon inﬂammation in the urine of the
IL10−/− mouse. This paper extends those observations rais-
ing wider questions about the role of tryptophan catabolism
and xanthurenic acid conjugates in the regulation of urinary
salt balance [27] and inﬂammation.
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